Eli Lilly: positive phase III results for migraine treatment
(CercleFinance.com) - Over the weekend, Eli Lilly disclosed positive results from three phase 3 studies on galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine.
In both studies, patients with episodic migraine treated with galcanezumab over a six-month treatment period experienced a statistically significant greater decrease in the average number of headache days compared to patients treated with placebo.
A statistically significant higher percentage of patients treated with both doses of galcanezumab achieved at least a 50%, 75% and 100% reduction in the number of migraine headache days compared to placebo in both studies.
Based on these results, Lilly plans to submit a Biologics License Application to the US Food and Drug Administration (FDA) for galcanezumab in the second half of 2017, followed by submissions to other regulatory agencies around the world.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In both studies, patients with episodic migraine treated with galcanezumab over a six-month treatment period experienced a statistically significant greater decrease in the average number of headache days compared to patients treated with placebo.
A statistically significant higher percentage of patients treated with both doses of galcanezumab achieved at least a 50%, 75% and 100% reduction in the number of migraine headache days compared to placebo in both studies.
Based on these results, Lilly plans to submit a Biologics License Application to the US Food and Drug Administration (FDA) for galcanezumab in the second half of 2017, followed by submissions to other regulatory agencies around the world.
Copyright (c) 2017 CercleFinance.com. All rights reserved.